Concepedia

Economic evaluation of the impact of nicorandil in angina (IONA) trial

Andrew Walker, John J.V. McMurray, Simon Stewart, WE Berger, A D McMahon, H. J. Dargie, Kevin Fox, S Hillis, N J K Henderson, Ian Ford

Heart · 2006 · 25 citations · 15 references

DOIFull text

Open access

Abstract

A substantial amount of the additional cost of nicorandil is offset by reduced use of hospital services. The limited comparisons possible with other CHD interventions suggest that nicorandil compares favourably.

References

15

Effect of nicorandil on coronary events in patients with stable angina: the Impact of Nicorandil in Angina (IONA) randomised trial

ACC Current Journal Review · 2002 · 501 citations

, , +6

Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model.

Milton C. Weinstein, Pam Coxson, L W Williams et al. · American Journal of Public Health · 1987 · 363 citations

, , +17

Cost Effectiveness of Aspirin, Clopidogrel, or Both for Secondary Prevention of Coronary Heart Disease

Jean-Michel Gaspoz, Pamela G. Coxson, Paula A. Goldman et al. · New England Journal of Medicine · 2002 · 293 citations · Full text

Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: the future rise of heart failure.

Luc Bonneux, Jan J. Barendregt, K Meeter et al. · American Journal of Public Health · 1994 · 281 citations · Full text

The economic burden of coronary heart disease in the UK

J L Y Liu · Heart · 2002 · 201 citations · Full text